Befotertinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Befotertinib
- Molecular weight
- 567.62
- Structure (SMILES)
- C=CC(=O)Nc1cc(Nc2nccc(-c3cn(CC(F)(F)F)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C
- 2 propenamide n 2 2 dimethylamino ethyl methylamino 4 methoxy 5 4 1 2 2 2 trifluoroethyl 1h indol 3 yl 2 pyrimidinyl amino phenyl
- 2-PROPENAMIDE, N-(2-((2-(DIMETHYLAMINO)ETHYL)METHYLAMINO)-4-METHOXY-5-((4-(1-(2,2,2-TRIFLUOROETHYL)-1H-INDOL-3-YL)-2-PYRIMIDINYL)AMINO)PHENYL)-
- befotertinib
- Befotertinib
- befotertinib [INN]
- Befotertinib [WHO-DD]
- befotertinib inn
- befotertinib who dd
- d 0316
- D 0316
- D-0316
- D-0316 Capsule
- d0316
- D0316
- CAS registry numbers
- 1835667-63-4
- ChEMBL ID
- CHEMBL5095167
- InChIKey
- USOCZVZOXKTJTI-UHFFFAOYSA-N
- PubChem compound IDs
- 130412842
- FDA ingredient codes (UNII)
- 0XT2CPR891
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- befotertinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- EGFR
- Protein identifier
- P00533
Investigated indications
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- NCT03452150
- NCT04206072
- NCT04464551
- NCT05007938
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 87.55
- Calculated partition coefficient (ALogP)
- 5.54
- Calculated partition coefficient (XLogP)
- 4.8
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 41
- Molecular formula
- C29H32F3N7O2
- Monoisotopic mass
- 567.25695778
- Natural product
- No
Related records
Trials (13)
- Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
- Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
- Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
- Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
- ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
- D-0316 First Time in Patients Ascending Dose Study
- D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
- Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
- Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
- Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
- Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
- The Absorption, Metabolism and Excretion of [14C]D-0316 in Human
In development for (1)
- Non-small cell lung carcinoma Phase 2